9FQA

Crystal structure of SARS-CoV-2 main protease (MPro) in complex with the covalently bound inhibitor PSB-21101 (compound 30b in publication)


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.47 Å
  • R-Value Free: 0.241 
  • R-Value Work: 0.203 
  • R-Value Observed: 0.205 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.0 of the entry. See complete history


Literature

Nonpeptidic Irreversible Inhibitors of SARS-CoV-2 Main Protease with Potent Antiviral Activity.

Oneto, A.Hamwi, G.A.Schakel, L.Kruger, N.Sylvester, K.Petry, M.Shamleh, R.A.Pillaiyar, T.Claff, T.Schiedel, A.C.Strater, N.Gutschow, M.Muller, C.E.

(2024) J Med Chem 

  • DOI: https://doi.org/10.1021/acs.jmedchem.4c00535
  • Primary Citation of Related Structures:  
    9FQ9, 9FQA

  • PubMed Abstract: 

    SARS-CoV-2 infections pose a high risk for vulnerable patients. In this study, we designed benzoic acid halopyridyl esters bearing a variety of substituents as irreversible inhibitors of the main viral protease (M pro ). Altogether, 55 benzoyl chloro/bromo-pyridyl esters were synthesized, with broad variation of the substitution pattern on the benzoyl moiety. A workflow was employed for multiparametric optimization, including M pro inhibition assays of SARS-CoV-2 and related pathogenic coronaviruses, the duration of enzyme inhibition, the compounds' stability versus glutathione, cytotoxicity, and antiviral activity. Several compounds showed IC 50 values in the low nanomolar range, k inact / K i values of >100,000 M -1 s -1 and high antiviral activity. High-resolution X-ray cocrystal structures indicated an important role of ortho -fluorobenzoyl substitution, forming a water network that stabilizes the inhibitor-bound enzyme. The most potent antiviral compound was the p -ethoxy- o -fluorobenzoyl chloropyridyl ester (PSB-21110, 29b , MW 296 g/mol; EC 50 2.68 nM), which may serve as a lead structure for broad-spectrum anticoronaviral therapeutics.


  • Organizational Affiliation

    Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, Bonn D-53121, Germany.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Non-structural protein 11306Severe acute respiratory syndrome coronavirus 2Mutation(s): 0 
UniProt
Find proteins for P0DTC1 (Severe acute respiratory syndrome coronavirus 2)
Explore P0DTC1 
Go to UniProtKB:  P0DTC1
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP0DTC1
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 3 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
A1IEY (Subject of Investigation/LOI)
Query on A1IEY

Download Ideal Coordinates CCD File 
B [auth A](5-chloranylpyridin-3-yl) 2-fluoranyl-4-phenylmethoxy-benzoate
C19 H13 Cl F N O3
KPTCFQSFRDOBIJ-UHFFFAOYSA-N
BR
Query on BR

Download Ideal Coordinates CCD File 
D [auth A]BROMIDE ION
Br
CPELXLSAUQHCOX-UHFFFAOYSA-M
MG
Query on MG

Download Ideal Coordinates CCD File 
C [auth A]MAGNESIUM ION
Mg
JLVVSXFLKOJNIY-UHFFFAOYSA-N
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.47 Å
  • R-Value Free: 0.241 
  • R-Value Work: 0.203 
  • R-Value Observed: 0.205 
  • Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 96.534α = 90
b = 81.215β = 114.69
c = 51.57γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
XDSdata reduction
STARANISOdata scaling
PHENIXphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Volkswagen FoundationGermany9A894
Volkswagen FoundationGermany9A850

Revision History  (Full details and data files)

  • Version 1.0: 2024-08-28
    Type: Initial release